odronextamab

Home
Ligands
odronextamab

GtoPdb Ligand ID: 12690

Synonyms: Ordspono® | REGN-1979 | REGN1979

odronextamab is an approved drug (EMA (2024))

Comment: Odronextamab (REGN1979) is a fully human CD3ε/CD20 bispecific IgG4-based antibody that redirects CD3⁺ cytotoxic T cells to selectively destroy CD20+ve malignant B cells [3]. Fc-mediated effector function has been minimised by modification of the IgG4 Fc domain.

References
1. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J et al.. (2022) Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol, 9 (5): e327-e339. [PMID:35366963]
2. Blair HA. (2024) Odronextamab: First Approval. Drugs, 84 (12): 1651-1658. [PMID:39557796]
3. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J et al.. (2015) A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep, 5: 17943. [PMID:26659273]

References

1. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J et al.. (2022)
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Lancet Haematol, 9 (5): e327-e339. [PMID:35366963]

2. Blair HA. (2024)
Odronextamab: First Approval.
Drugs, 84 (12): 1651-1658. [PMID:39557796]

3. Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J et al.. (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Sci Rep, 5: 17943. [PMID:26659273]